Skip to main content
SpringerLink
Log in

Is paclitaxel/carboplatin really a useful regimen for ovarian cancer compared with platinum/doxorubicin/cyclophosphamide?

  • EDITORIAL
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. R Numazaki E Miyagi R Onose et al. (2006) ArticleTitleHistorical control study of paclitaxel-carboplatin (TJ) versus conventional platinum-based chemotherapy (CAP) for epithelial ovarian cancer Int J Clin Oncol 11 221–228 Occurrence Handle16850129 Occurrence Handle1:CAS:528:DC%2BD28XntVGju7o%3D

    PubMed  CAS  Google Scholar 

  2. WP McGuire WJ Hoskins MF Brady et al. (1996) ArticleTitleCyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer (GOG 111) N Engl J Med 334 1–6 Occurrence Handle7494563 Occurrence Handle1:CAS:528:DyaK28XhtFKiur4%3D Occurrence Handle10.1056/NEJM199601043340101

    Article  PubMed  CAS  Google Scholar 

  3. MJ Piccart K Bertelsen K James et al. (2000) ArticleTitleRandomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cacer: 3-year results (OV-10) J Natl Cancer Inst 92 699–708 Occurrence Handle10793106 Occurrence Handle1:CAS:528:DC%2BD3cXjslSns7c%3D Occurrence Handle10.1093/jnci/92.9.699

    Article  PubMed  CAS  Google Scholar 

  4. InstitutionalAuthorNameThe International Collaborative Ovarian Neoplasm (ICON) Group (2002) ArticleTitlePaclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial Lancet 360 505–515 Occurrence Handle10.1016/S0140-6736(02)09738-6

    Article  Google Scholar 

  5. RF Ozols BN Bundy BE Greer et al. (2003) ArticleTitlePhase III trial carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study (GOG 158) J Clin Oncol 21 3194–3200 Occurrence Handle12860964 Occurrence Handle1:CAS:528:DC%2BD2cXps1aktbk%3D Occurrence Handle10.1200/JCO.2003.02.153

    Article  PubMed  CAS  Google Scholar 

  6. A Du Bois HJ Luck W Meier et al. (2003) ArticleTitleA randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer (AGO) J Natl Cancer Inst 95 1320–1329 Occurrence Handle12953086 Occurrence Handle1:CAS:528:DC%2BD3sXntVKhurg%3D

    PubMed  CAS  Google Scholar 

  7. PA Vasey GC Jayson A Gordon et al. (2004) ArticleTitlePhase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma (SCOTROC) J Natl Cancer Inst 96 1682–1691 Occurrence Handle15547181 Occurrence Handle1:CAS:528:DC%2BD2cXhtVSqsrzJ Occurrence Handle10.1093/jnci/djh323

    Article  PubMed  CAS  Google Scholar 

  8. R Yamamoto S Minobe M Kaneuchi et al. (2002) ArticleTitleA phase I/II study of carboplatin and paclitaxel in patients with epithelial ovarian cancer Jpn J Clin Oncol 32 128–134 Occurrence Handle12072422 Occurrence Handle10.1093/jjco/hyf029

    Article  PubMed  Google Scholar 

  9. Y Takei M Suzuki Y Ohwada et al. (2003) ArticleTitleA feasibility study of paclitaxel and carboplatin therapy in Japanese patients with epithelial ovarian cancer Oncol Rep 10 951–955 Occurrence Handle12792751 Occurrence Handle1:CAS:528:DC%2BD3sXltFGlt78%3D

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, Iwate, 020-8505, Japan

    Toru Sugiyama M.D.

Authors
  1. Toru Sugiyama M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Sugiyama, T. Is paclitaxel/carboplatin really a useful regimen for ovarian cancer compared with platinum/doxorubicin/cyclophosphamide?. Int J Clin Oncol 11, 163 (2006). https://doi.org/10.1007/s10147-006-0572-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-006-0572-7

Keywords

Search

Navigation